{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:35:21Z","timestamp":1792607721861,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This analysis aims to evaluate health-related quality of life (HrQoL) (primary outcome for this analysis), nausea and vomiting, and pain in patients with inoperable malignant bowel obstruction (IMBO) due to cancer or its treatments randomised to standardised therapies plus octreotide or placebo over a maximum of 72\u2009h in a double-blind clinical trial.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Adults with IMBO and vomiting recruited through 12 services spanning inpatient, consultative and community settings in Australia were randomised to subcutaneous octreotide infusion or saline. HrQoL was measured at baseline and treatment cessation (EORTC QLQ-C15-PAL). Mean within-group paired differences between baseline and post-treatment scores were analysed using Wilcoxon Signed Rank test and between group differences estimated using linear mixed models, adjusted for baseline score, sex, age, time, and study arm.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One hundred six of the 112 randomised participants were included in the analysis (<jats:italic>n<\/jats:italic>\u00a0=\u200952 octreotide, <jats:italic>n<\/jats:italic>\u00a0=\u200954 placebo); 6 participants were excluded due to major protocol violations. Mean baseline HrQoL scores were low (octreotide 22.1, 95% CI 14.3, 29.9; placebo 31.5, 95% CI 22.3, 40.7). There was no statistically significant within-group improvement in the mean HrQoL scores in the octreotide (<jats:italic>p<\/jats:italic>\u00a0=\u20090.21) or placebo groups (<jats:italic>p<\/jats:italic>\u00a0=\u20090.78), although both groups reported reductions in mean nausea and vomiting (octreotide <jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.01; placebo <jats:italic>p<\/jats:italic>\u00a0=\u20090.02) and pain scores (octreotide <jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.01; placebo <jats:italic>p<\/jats:italic>\u00a0=\u20090.03). Although no statistically significant difference in changes in HrQoL scores between octreotide and placebo were seen, an adequately powered study is required to fully assess any differences in HrQoL scores.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The HrQoL of patients with IMBO and vomiting is poor. Further research to formally evaluate the effects of standard therapies for IMBO is therefore warranted.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Australian New Zealand Clinical Trials Registry <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=82724\">ACTRN12608000211369<\/jats:ext-link> (date registered 18\/04\/2008)<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-020-07549-y","type":"journal-article","created":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T14:02:43Z","timestamp":1604152963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3684-3723","authenticated-orcid":false,"given":"Nikki","family":"McCaffrey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tegan","family":"Asser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Fazekas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Muircroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Agar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Eckermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Allcroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Sheehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Currow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,31]]},"reference":[{"key":"7549_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/CMAR.S29297","volume":"4","author":"A Tuca","year":"2012","unstructured":"Tuca A, Guell E, Martinez-Losada E, Codorniu N. Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution. Cancer Manag Res. 2012;4:159\u201369.","journal-title":"Cancer Manag Res"},{"issue":"2","key":"7549_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jpainsymman.2006.06.014","volume":"33","author":"S Mercadante","year":"2007","unstructured":"Mercadante S, Casuccio A, Mangione S. Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. J Pain Symptom Manag. 2007;33(2):217\u201323.","journal-title":"J Pain Symptom Manag"},{"issue":"4","key":"7549_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s005200000198","volume":"9","author":"C Ripamonti","year":"2001","unstructured":"Ripamonti C, Twycross R, Baines M, Bozzetti F, Capri S, De Conno F, Gemlo B, Hunt TM, Krebs HB, Mercadante S, Schaerer R, Wilkinson P. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer. 2001;9(4):223\u201333.","journal-title":"Support Care Cancer"},{"issue":"5","key":"7549_CR4","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jpainsymman.2014.09.013","volume":"49","author":"DC Currow","year":"2015","unstructured":"Currow DC, Quinn S, Agar M, Fazekas B, Hardy J, McCaffrey N, Eckermann S, Abernethy AP, Clark K. Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. J Pain Symptom Manag. 2015;49(5):814\u201321.","journal-title":"J Pain Symptom Manag"},{"issue":"9","key":"7549_CR5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMra1510064","volume":"375","author":"SJ Pocock","year":"2016","unstructured":"Pocock SJ, Stone GW. The primary outcome fails \u2014 what next? N Engl J Med. 2016;375(9):861\u201370.","journal-title":"N Engl J Med"},{"issue":"3","key":"7549_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/082585971503100302","volume":"31","author":"K Kindl","year":"2015","unstructured":"Kindl K, Good P. Evidence-based palliative care 13 years on: has anything changed? J Palliat Care. 2015;31(3):133\u201340.","journal-title":"J Palliat Care"},{"issue":"8","key":"7549_CR7","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/jjco\/hyq048","volume":"40","author":"T Hisanaga","year":"2010","unstructured":"Hisanaga T, Shinjo T, Morita T, Nakajima N, Ikenaga M, Tanimizu M, Kizawa Y, Maeno T, Shima Y, Hyodo I. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction. Jpn J Clin Oncol. 2010;40(8):739\u201345.","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"7549_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jpainsymman.2005.05.018","volume":"30","author":"UA Matulonis","year":"2005","unstructured":"Matulonis UA, Seiden MV, Roche M, Krasner C, Fuller AF, Atkinson T, Kornblith A, Penson R. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. J Pain Symptom Manag. 2005;30(6):563\u20139.","journal-title":"J Pain Symptom Manag"},{"issue":"5","key":"7549_CR9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/jjco\/hyn035","volume":"38","author":"Y Shima","year":"2008","unstructured":"Shima Y, Ohtsu A, Shirao K, Sasaki Y. Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction. Jpn J Clin Oncol. 2008;38(5):354\u20139.","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"7549_CR10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ajo.2009.08.001","volume":"149","author":"JJ Wang","year":"2010","unstructured":"Wang JJ, Attia J. Study designs in epidemiology and levels of evidence. Am J Ophthalmol. 2010;149(3):367\u201370.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"7549_CR11","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.jpainsymman.2016.05.032","volume":"52","author":"GP Obita","year":"2016","unstructured":"Obita GP, Boland EG, Currow DC, Johnson MJ, Boland JW. Somatostatin analogues compared with placebo and other pharmacologic agents in the management of symptoms of inoperable malignant bowel obstruction: a systematic review. J Pain Symptom Manage. 2016;52(6):901\u201319.e1.","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"7549_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/0269216309346544","volume":"24","author":"D Selby","year":"2010","unstructured":"Selby D, Wright F, Stilos K, Daines P, Moravan V, Gill A, Chakraborty A. Room for improvement? A quality-of-life assessment in patients with malignant bowel obstruction. Palliat Med. 2010;24(1):38\u201345.","journal-title":"Palliat Med"},{"issue":"5","key":"7549_CR13","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.clnu.2014.09.010","volume":"34","author":"M Naghibi","year":"2015","unstructured":"Naghibi M, Smith TR, Elia M. A systematic review with meta-analysis of survival, quality of life and cost-effectiveness of home parenteral nutrition in patients with inoperable malignant bowel obstruction. Clin Nutr. 2015;34(5):825\u201337.","journal-title":"Clin Nutr"},{"key":"7549_CR14","doi-asserted-by":"publisher","first-page":"1867238","DOI":"10.1155\/2018\/1867238","volume":"2018","author":"YC Lee","year":"2018","unstructured":"Lee YC, Jivraj N, O'Brien C, Chawla T, Shlomovitz E, Buchanan S, Lau J, Croke J, Allard JP, Dhar P, Laframboise S, Ferguson SE, Dhani N, Butler M, Ng P, Stuart-McEwan T, Savage P, Tinker L, Oza AM, Lheureux S. Malignant bowel obstruction in advanced gynecologic cancers: an updated review from a multidisciplinary perspective. Obstet Gynecol Int. 2018;2018:1867238.","journal-title":"Obstet Gynecol Int"},{"key":"7549_CR15","volume-title":"European Journal of Palliative Care 2017:173; EAPC 2017, 18-20 May, Madrid, Spain","author":"N McCaffrey","year":"2017","unstructured":"McCaffrey N, Asser T, Fazekas B, Muircroft W, Clark K, Currow D. Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary endpoint from the double-blind, placebo-controlled randomised trial of octreotide [abstract]. In: European Journal of Palliative Care 2017:173; EAPC 2017, 18-20 May, Madrid, Spain. Milan: Hayward Group Ltd; 2017. Abstract number FC12."},{"issue":"1","key":"7549_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1071\/AH15012","volume":"40","author":"N McCaffrey","year":"2016","unstructured":"McCaffrey N, Hardy J, Fazekas B, Agar M, Devilee L, Rowett D, Currow D. Potential economic impact on hospitalisations of the Palliative Care Clinical Studies Collaborative (PaCCSC) ketamine randomised controlled trial. Aust Health Rev. 2016;40(1):100\u20135.","journal-title":"Aust Health Rev"},{"issue":"2","key":"7549_CR17","first-page":"129","volume":"23","author":"CS Cleeland","year":"1994","unstructured":"Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singap. 1994;23(2):129\u201338.","journal-title":"Ann Acad Med Singap"},{"key":"7549_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1472-684X-4-7","volume":"4","author":"AP Abernethy","year":"2005","unstructured":"Abernethy AP, Shelby-James T, Fazekas BS, Woods D, Currow DC. The Australia-modified Karnofsky Performance Status (AKPS) scale: a revised scale for contemporary palliative care clinical practice [ISRCTN81117481]. BMC Palliat Care. 2005;4:7.","journal-title":"BMC Palliat Care"},{"key":"7549_CR19","volume-title":"A randomised double blind placebo controlled trial of infusional subcutaneous octreotide in the management of malignant bowel obstruction at the end of life","author":"Australian New Zealand Clinical Trials Registry","year":"2008","unstructured":"Australian New Zealand Clinical Trials Registry. A randomised double blind placebo controlled trial of infusional subcutaneous octreotide in the management of malignant bowel obstruction at the end of life. Sydney: NHMRC Clinical Trials Centre, University of Sydney (Australia); 2008."},{"issue":"1","key":"7549_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejca.2005.06.022","volume":"42","author":"M Groenvold","year":"2006","unstructured":"Groenvold M, Petersen MA, Aaronson NK, Arraras JI, Blazeby JM, Bottomley A, Fayers PM, de Graeff A, Hammerlid E, Kaasa S, Sprangers MA, Bjorner JB. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer. 2006;42(1):55\u201364.","journal-title":"Eur J Cancer"},{"issue":"4","key":"7549_CR21","doi-asserted-by":"publisher","first-page":"e94316","DOI":"10.1371\/journal.pone.0094316","volume":"9","author":"N McCaffrey","year":"2014","unstructured":"McCaffrey N, Skuza P, Breaden K, Eckermann S, Hardy J, Oaten S, Briffa M, Currow D. Preliminary development and validation of a new end-of-life patient-reported outcome measure assessing the ability of patients to finalise their Affairs at the end of life. PLoS One. 2014;9(4):e94316.","journal-title":"PLoS One"},{"key":"7549_CR22","volume-title":"The EORTC QLQ-C30 scoring manual","author":"PM Fayers","year":"2001","unstructured":"Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 scoring manual. 3rd ed. Belgium: EORTC Data Center; 2001.","edition":"3"},{"key":"7549_CR23","volume-title":"Addendum to the EORTC QLQ-C30 scoring manual: scoring of the EORTC QLQ-C15-PAL","author":"M Groenvold","year":"2006","unstructured":"Groenvold M, Petersen M, on behalf of the EORTC Quality of Life Group. Addendum to the EORTC QLQ-C30 scoring manual: scoring of the EORTC QLQ-C15-PAL. 2006."},{"key":"7549_CR24","doi-asserted-by":"publisher","unstructured":"Moher D, Hopewell S, Schulz KF, Montori V, G\u00f8tzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340. \n                  https:\/\/doi.org\/10.1136\/bmj.c869\n                  \n                .","DOI":"10.1136\/bmj.c869"},{"key":"7549_CR25","doi-asserted-by":"crossref","unstructured":"Schulz KF, Altman DG, Moher D.CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. \n                  https:\/\/www.bmj.com\/content\/340\/bmj.c332\n                  \n                .","DOI":"10.1136\/bmj.c332"},{"key":"7549_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/CLEP.S72247","volume":"7","author":"K Biering","year":"2015","unstructured":"Biering K, Hjollund NH, Frydenberg M. Using multiple imputation to deal with missing data and attrition in longitudinal studies with repeated measures of patient-reported outcomes. Clin Epidemiol. 2015;7:91\u2013106.","journal-title":"Clin Epidemiol"},{"issue":"4","key":"7549_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","volume":"30","author":"IR White","year":"2011","unstructured":"White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4):377\u201399.","journal-title":"Stat Med"},{"issue":"6","key":"7549_CR28","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/BF00439229","volume":"5","author":"MT King","year":"1996","unstructured":"King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res. 1996;5(6):555\u201367.","journal-title":"Qual Life Res"},{"issue":"1","key":"7549_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139\u201344.","journal-title":"J Clin Oncol"},{"issue":"10","key":"7549_CR30","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1007\/s11136-016-1308-4","volume":"25","author":"S Raman","year":"2016","unstructured":"Raman S, Ding K, Chow E, Meyer RM, Nabid A, Chabot P, Coulombe G, Ahmed S, Kuk J, Dar AR, Mahmud A, Fairchild A, Wilson CF, Wu JSY, Dennis K, DeAngelis C, Wong RKS, Zhu L, Brundage M. Minimal clinically important differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-PAL modules in patients with bone metastases undergoing palliative radiotherapy. Qual Life Res. 2016;25(10):2535\u201341.","journal-title":"Qual Life Res"},{"issue":"1","key":"7549_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/1471-2407-12-283","volume":"12","author":"D Steinmann","year":"2012","unstructured":"Steinmann D, Paelecke-Habermann Y, Geinitz H, Aschoff R, Bayerl A, Bolling T, Bosch E, Bruns F, Eichenseder-Seiss U, Gerstein J, Gharbi N, Hagg J, Hipp M, Kleff I, Muller A, Schafer C, Schleicher U, Sehlen S, Theodorou M, Wypior H-J, Zehentmayr F, van Oorschot B, Vordermark D. Prospective evaluation of quality of life effects in patients undergoing palliative radiotherapy for brain metastases. BMC Cancer. 2012;12(1):283.","journal-title":"BMC Cancer"},{"key":"7549_CR32","volume-title":"SPSS survival manual: a step by step guide to data analysis using SPSS","author":"J Pallant","year":"2011","unstructured":"Pallant J. SPSS survival manual: a step by step guide to data analysis using SPSS. 4th ed. Crows Nest: Allen and Unwin; 2011.","edition":"4"},{"issue":"7","key":"7549_CR33","doi-asserted-by":"publisher","first-page":"e0181387","DOI":"10.1371\/journal.pone.0181387","volume":"12","author":"KE Bell","year":"2017","unstructured":"Bell KE, Snijders T, Zulyniak M, Kumbhare D, Parise G, Chabowski A, Phillips SM. A whey protein-based multi-ingredient nutritional supplement stimulates gains in lean body mass and strength in healthy older men: a randomized controlled trial. PLoS One. 2017;12(7):e0181387.","journal-title":"PLoS One"},{"key":"7549_CR34","volume-title":"Inference part II: covariance components. Generalized linear mixed models: modern concepts, methods and applications","author":"W Stroup","year":"2013","unstructured":"Stroup W. Inference part II: covariance components. Generalized linear mixed models: modern concepts, methods and applications. Boca Raton: CEC Press, Taylor & Francis Group, LLC; 2013."},{"issue":"1","key":"7549_CR35","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12955-016-0537-0","volume":"14","author":"N McCaffrey","year":"2016","unstructured":"McCaffrey N, Kaambwa B, Currow DC, Ratcliffe J. Health-related quality of life measured using the EQ-5D-5L: south Australian population norms. Health Qual Life Outcomes. 2016;14(1):133.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"7549_CR36","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jpainsymman.2016.02.012","volume":"52","author":"N McCaffrey","year":"2016","unstructured":"McCaffrey N, Bradley S, Ratcliffe J, Currow DC. What aspects of quality of life are important from palliative care patients\u2019 perspectives? A systematic review of qualitative research. J Pain Symptom Manage. 2016;52(2):318\u201328.e5.","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"7549_CR37","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1586\/erp.11.64","volume":"11","author":"K Lien","year":"2011","unstructured":"Lien K, Zeng L, Nguyen J, Cramarossa G, Culleton S, Caissie A, Lutz S, Chow E. Comparison of the EORTC QLQ-C15-PAL and the FACIT-Pal for assessment of quality of life in patients with advanced cancer. Expert Rev Pharmacoecon Outcomes Res. 2011;11(5):541\u20137.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07549-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-07549-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07549-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T18:03:48Z","timestamp":1604426628000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07549-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,31]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7549"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07549-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,31]]},"assertion":[{"value":"15 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This PaCCSC RCT was approved by the following ethics committees across Australia (see ).- Repatriation General Hospital Research and Ethics Committee, South Australia (EC00191)- Mater Health Services Human Research Ethics Committee, Mater Health Service, Queensland (EC00332)- Ballarat Health Services & St John of God Health Care Ethics Committee, Ballarat Health Services, Victoria (EC00326)- Alfred Hospital Ethics Committee, Victoria (EC00266)- Hollywood Private Hospital Research Ethics Committee, Western Australia (EC00266)- St John of God Health Care Ethics Committee, Western Australia (EC00414)- Peter MacCallum Cancer Centre Ethics Committee, Peter MacCallum Cancer Centre, Victoria (EC00235)Participants provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Professor Currow is an unpaid member of an advisory board for Helsinn Pharmaceuticals, is a consultant to Specialized Therapeutics and Mayne Pharma and received intellectual property payments from Mayne Pharma. All other authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1050"}}